Literature DB >> 34759012

The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.

Erin C Berthold1, Shyam H Kamble1, Kanumuri S Raju1, Michelle A Kuntz1, Alexandria S Senetra1, Marco Mottinelli1, Francisco León1, Luis F Restrepo1, Avi Patel1, Nicholas P Ho1, Takato Hiranita1, Abhisheak Sharma1, Lance R McMahon1, Christopher R McCurdy2.   

Abstract

Kratom (Mitragyna speciosa), a Southeast Asian tree, has been used for centuries in pain relief and mitigation of opium withdrawal symptoms. Mitragynine (MTG), the major kratom alkaloid, is being investigated for its potential to provide analgesia without the deleterious effects associated with typical opioids. Concerns have been raised regarding the active metabolite of MTG, 7-hydroxymitragynine (7HMG), which has higher affinity and efficacy at µ-opioid receptors than MTG. Here we investigated the hotplate antinociception, pharmacokinetics, and tissue distribution of MTG and 7HMG at equianalgesic oral doses in male and female C57BL/6 mice to determine the extent to which 7HMG metabolized from MTG accounts for the antinociceptive effects of MTG and investigate any sex differences. The mechanism of action was examined by performing studies with the opioid receptor antagonist naltrexone. A population pharmacokinetic/pharmacodynamic model was developed to predict the behavioral effects after administration of various doses of MTG and 7HMG. When administered alone, 7HMG was 2.8-fold more potent than MTG to produce antinociception. At equivalent effective doses of MTG and 7HMG, there was a marked difference in the maximum brain concentration of 7HMG achieved, i.e., 11-fold lower as a metabolite of MTG. The brain concentration of 7HMG observed 4 hours post administration, producing an analgesic effect <10%, was still 1.5-fold higher than the maximum concentration of 7HMG as a metabolite of MTG. These results provide strong evidence that 7HMG has a negligible role in the antinociceptive effects of MTG in mice. SIGNIFICANCE STATEMENT: Mitragynine (MTG) is being investigated for its potential to aid in pain relief, opioid withdrawal syndrome, and opioid use disorder. The active metabolite of MTG, 7-hydroxymitragynine (7HMG), has been shown to have abuse potential and has been implicated in the opioid-like analgesic effect after MTG administration. The results of this study suggest a lack of involvement of 7HMG in the antinociceptive effects of MTG in mice.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34759012      PMCID: PMC8969138          DOI: 10.1124/dmd.121.000640

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

1.  A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery.

Authors:  Shaoxia Yu; Shelly Li; Hua Yang; Frank Lee; Jing-Tao Wu; Mark G Qian
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

2.  Developmental changes in opiate-induced analgesia in deer mice: sex and population differences.

Authors:  M Kavaliers; D G Innes
Journal:  Brain Res       Date:  1990-05-21       Impact factor: 3.252

3.  Evaluation of in vitro absorption, distribution, metabolism, and excretion (ADME) properties of mitragynine, 7-hydroxymitragynine, and mitraphylline.

Authors:  Vamshi K Manda; Bharathi Avula; Zulfiqar Ali; Ikhlas A Khan; Larry A Walker; Shabana I Khan
Journal:  Planta Med       Date:  2014-05-19       Impact factor: 3.352

4.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

5.  Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom).

Authors:  Shyam H Kamble; Abhisheak Sharma; Tamara I King; Francisco León; Christopher R McCurdy; Bonnie A Avery
Journal:  Xenobiotica       Date:  2019-01-07       Impact factor: 1.908

6.  Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Authors:  Kai Yue; Theresa A Kopajtic; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2018-07-23       Impact factor: 4.530

7.  Morphine-induced straub tail response: mediated by central mu2-opioid receptor.

Authors:  C Nath; M B Gupta; G K Patnaik; K N Dhawan
Journal:  Eur J Pharmacol       Date:  1994-09-22       Impact factor: 4.432

8.  Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.

Authors:  Samuel Obeng; Shyam H Kamble; Morgan E Reeves; Luis F Restrepo; Avi Patel; Mira Behnke; Nelson J-Y Chear; Surash Ramanathan; Abhisheak Sharma; Francisco León; Takato Hiranita; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2019-12-27       Impact factor: 7.446

9.  Current perspectives on the impact of Kratom use.

Authors:  Charles Veltri; Oliver Grundmann
Journal:  Subst Abuse Rehabil       Date:  2019-07-01

Review 10.  Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.

Authors:  Steven C Eastlack; Elyse M Cornett; Alan D Kaye
Journal:  Pain Ther       Date:  2020-01-28
View more
  1 in total

1.  Kratom alkaloid mitragynine: Inhibition of chemotherapy-induced peripheral neuropathy in mice is dependent on sex and active adrenergic and opioid receptors.

Authors:  Daniel J Farkas; Jeffery D Foss; Sara Jane Ward; Scott M Rawls
Journal:  IBRO Neurosci Rep       Date:  2022-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.